ArticleJAMA dermatology2025
Local Recurrence and Survival in Patients With Melanoma In Situ.
Article in JAMA dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Narrow Excision Margins for Diverse Histological Subtypes of Cutaneous Melanoma in Children and Adults: A Systematic Review.Dermatology and therapy · 2026Pooled it
- Overdiagnosis of Melanoma In Situ.Journal of clinical medicine · 2026Review
- Advances in the treatment of cutaneous tumors: from conventional therapies to targeted and immunotherapeutic strategies.World journal of surgical oncology · 2026Review
- Retro- and prospective histologic and immunohistochemical analysis of safety margins following complete excision of less than 1 mm melanomas.Melanoma research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The overdiagnosis of melanoma in situ (MIS) is well documented. There is limited evidence on the rate of local recurrence of the non-lentigo maligna (non-LM)/non-acral lentiginous melanoma (non-ALM) subtypes. Objective: To investigate local recurrence and prognosis in non-LM/non-ALM MIS, the histopathological clearance of the excisional biopsy margins, and the association with the size of wide excision margins. Design, Setting, and Participants: This retrospective cohort study included patients with non-LM/non-ALM MIS diagnosed from 1991 to 2023 who were followed up for at least 1 year at the Skin Cancer and Melanoma Unit of Andreas Sygros University Hospital in Athens, Greece. Patients with a history of invasive melanoma or a histopathological diagnosis of LM or ALM in situ were excluded. Median (IQR) follow-up was 5.2 (2.9-7.9) years. Deidentified data on patient demographics and clinical characteristics, including the histopathological clearance of margins of the initial excisional biopsy and the size of margins of the wide excision, were obtained from medical records. Main Outcomes and Measures: The primary outcomes were local recurrence, metastasis, and melanoma-specific survival. Results: A total of 401 patients (214 [53.4%] women) with 403 non-LM/non-ALM MIS and a median (IQR) age of 52 (40-62) years were included in the analysis. MIS was frequently located on the trunk (201 lesions [49.9%]), followed by the lower extremity (99 [24.6%]), the upper extremity (71 [17.6%]), and the head and neck (32 [7.9%]). All lesions were initially treated with excisional biopsy, followed by wide excision for 372 (92.3%). There was only 1 local recurrence in a patient with involved margins at the excisional biopsy who did not undergo wide excision and developed an invasive melanoma 14 months later. Thirty lesions in 30 patients had clear excisional biopsy margins with no wide excision and had no recurrence at a median (IQR) follow-up of 8.1 (4.1-12.9) years. In 23 patients with 23 lesions that had wide excision with narrower than the standard 0.5-cm margins (mean [SD] margin size, 0.36 [0.07] cm), no recurrences were found at a median (IQR) follow-up of 4.3 (2.7-6.2) years. During follow-up, 6 patients (1.5%) developed a lesion suspicious for recurrence near the excision scar, which was excised and showed nevus or solar lentigo on histopathology. No patients had metastasis or melanoma-specific death. Conclusions and Relevance: This cohort study found that diagnostic excisional biopsies with clear margins may be sufficient for treating MIS; however, larger studies are necessary.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.